Your AI-Trained Oncology Knowledge Connection!
A pooled exploratory analysis of phase 3 trials found statistically significant progression-free survival and overall survival benefits with ribociclib/endocrine therapy for patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.
Findings from the phase 1b/2 KRYSTAL-1 trial showed encouraging responses with adagrasib in patients with advanced KRAS G12C-mutant colorectal cancer.
Treatment with fam-trastuzumab deruxtecan-nxki yielded promising patient-reported outcomes in patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to Naoto Ueno, MD, PhD.
Data from the phase 2 LITESPARK-003 trial demonstrated antitumor activity and a well-tolerated safety profile with belzutifan plus cabozantinib in patients with clear cell renal cell carcinoma.
Health-related quality of life data from the phase 2 KEYNOTE-522 trial did not show ill effects of pembrolizumab vs placebo in patients with triple-negative breast cancer.
Results from the LITESPARK-003 trial showed continued antitumor activity after 2 years with belzutifan plus cabozantinib.
Findings from the phase 3 PRESTO trial indicated that patients with high-risk biochemically recurrent prostate cancer may derive benefit from treatment with androgen deprivation therapy intensification and apalutamide.
Circulating tumor DNA levels could be a potential prognostic tool for predicting outcomes in diffuse large B-cell lymphoma.
Patients with mismatch repair deficient (dMMR) colon cancer experienced a high rate of major pathologic complete response following treatment with nivolumab and ipilimumab for 4 weeks.
In patients with non-germinal center B cell–like diffuse large B-cell lymphoma, the combination of orelabrutinib plus R-CHOP revealed an overall response rate of 86.4%.
Findings from Cohort K of the EV-103 trial demonstrated a 64.5% overall response rate with enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.
Findings from the phase 2 BIONIKK trial demonstrated an association between treatment efficacy and increased in situ and immune expression.
First results from the RADICALS-HD trial demonstrated improved metastasis-free survival with 2 years of androgen-deprivation therapy (ADT) plus radiotherapy in men with prostate cancer.
Patients with high-risk resectable melanoma experienced the highest event-free survival benefit when pembrolizumab was administered in the neoadjuvant settings vs the adjuvant setting
Trastuzumab deruxtecan demonstrates clinically meaningful benefit in patients with non¬–small cell lung cancer harboring HER2 mutations, according to results from the DESTINY-Lung02 trial.
Results from the phase 3 IPSOS trial showed a nearly doubled rate of 2-year overall survival with atezolizumab in patients with advanced non–small cell lung cancer.
Findings from the phase 1/2 ReFocus study highlighted that RLY-4008 is a potentially transformative agent for the treatment of FGFR inhibitor–naïve, FGFR-mutant cholangiocarcinoma.
The risk for disease progression or death was reduced by 27% with the addition of cabozantinib to nivolumab plus ipilimumab in patients with previously untreated renal cell carcinoma.
Result from the phase 3 KEYLINK-010 trial showed no statistically significant improvement in radiographic progression-free survival and overall survival when pembrolizumab and olaparib were used to treat molecularly unselected, previously treated metastatic castration-resistant prostate cancer vs novel hormonal agents.
Findings from the phase 3 CodeBreaK 200 trial show improved progression-free survival with sotorasib vs docetaxel in previously treated KRAS G12C-mutant non–small cell lung cancer.
Results from the phase 3 CANOPY-A trial failed to show improved disease-free survival with adjuvant canakinumab in completely resected non–small cell lung cancer.
Tucatinib as monotherapy and in combination with trastuzumab supported further investigation of the regimens in patients with metastatic HER2-positive colorectal cancer.
The final readout of the phase 2 TITAN-RCC trial highlighted an improvement in responses following an individualized regimen of nivolumab and ipilimumab boost after single-agent nivolumab in patients with advanced renal cell carcinoma.
Neoadjuvant treatment with cemiplimab led to near or complete disappearance of cutaneous squamous cell carcinoma in almost 64% of patients set to undergo surgery.
Findings from the phase 3 ADURA trial indicated that patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC) experienced a promising reduction in risk of disease recurrence or death following treatment with adjuvant osimertinib.
Findings from the DESTINY-Breast04 trial indicated that patients with hormone receptor–positive, HER2-low metastatic breast cancer experienced promising quality of life following treatment with fam-trastuzumab deruxtecan-nxki.
Patients with with metastatic castration-resistant prostate cancer continued to derive notable benefit from treatment with first-line olaparib plus abiraterone acetate and prednisone or prednisolone compared with abiraterone monotherapy.
Long-lasting duration of response and prolonged survival were observed following treatment with MEDI15752 vs pembrolizumab among patients with treatment-naïve nonsquamous non–small cell lung cancer, according to findings from a phase 1b/2 trial.
Patients with advanced clear cell renal cell carcinoma given lenvatinib plus pembrolizumab had sustained overall survival and progression-free survival benefit vs sunitinib, according to updated results of the CLEAR trial.
Results from a presentation at 2022 ESMO showed DCC-3116 was tolerated in patients with RAS or RAF-mutant solid tumors.
